Skip to main content
NewslettersWatchlist

Arch Biopartners Inc(ARCH-X)
TSX Venture

Today's Change
Delayed Last Update
Day Low1.860
Day High2.000
Open:1.960
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
AllPennyStocks.com
Dosing of First Patient in a Trial for LSALT Peptide is Sending Shares HIgher
GlobeNewswire
Arch Biopartners Announces Dosing of First Patient in Canada in the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
AI-generated - The Globe and Mail
Arch Biopartners: Top 10 Undervalued Healthcare Sector Stocks on TSX-V (ARCH)
GlobeNewswire
Arch Biopartners Arranges Non-Brokered Private Placement
GlobeNewswire
Closes Units for Debt Settlement
AI-generated - The Globe and Mail
Arch Biopartners: Top 10 Undervalued Healthcare Sector Stocks on TSX-V (ARCH)
GlobeNewswire
Units for Debt Settlement
GlobeNewswire
Arch Biopartners Announces Alberta Health Services Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI)
GlobeNewswire
Arch Biopartners’ Cilastatin Drug Candidate to Participate in the PONTIAC Phase II Trial Targeting Acute Kidney Injury Caused by Drug Toxins
GlobeNewswire
Arch Biopartners Closes Non-Brokered Private Placement
GlobeNewswire
Arch Biopartners Arranges Non-Brokered Private Placement
AI-generated - The Globe and Mail
Arch Biopartners: Top 10 Undervalued Healthcare Sector Stocks on TSX-V (ARCH)
GlobeNewswire
Arch Biopartners Announces GMP Manufacturing of Cilastatin Drug Product
GlobeNewswire
Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)
Baystreet
U.S. Eases into Memorial Day Weekend
GlobeNewswire
St. Michael’s Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
GlobeNewswire
UHN Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
GlobeNewswire
Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
GlobeNewswire
Arch Biopartners Clinical Team Publishes Data from Phase II Trial for LSALT Peptide Targeting Organ Inflammation in Hospitalized Patients Infected with SARS-CoV-2
GlobeNewswire
University of Calgary Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
GlobeNewswire
Arch Biopartners Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
GlobeNewswire
Arch Biopartners Has Pre-IND Meeting With FDA to Discuss Repurposing Cilastatin as a New Treatment to Prevent Acute Kidney Injury

Profile

Arch Biopartners Inc is a clinical stage company developing technologies with the potential to make medical or commercial impacts. The company is developing a drug platform Metablok to produce drug candidates to inhibit organ inflammation caused via the DPEP-1 pathway. It's under development portfolio is AB569, a potential new treatment for antibiotic resistant bacterial infections in the lungs or wounds; and, Borg peptide coatings that increase corrosion resistance and decrease bacterial biofilm on various medical grade metals and plastics.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.